

HIGHLIGHTS

Between 1 April and 31 March 2022, Cochrane South Africa (SA) staff published 79 articles in peer-reviewed ISI journals.

Staff contributed to one book chapter; 20 COVID-19 Rapid Review reports for the National Department of Health; one WHO consolidated guidelines on Tuberculosis; one Rapid Review report for the World Health Organization Africa Office and two Technical Reports 1) “Assessing the existing evidence base on school food and nutrition policies: a scoping review” for the for the World Health Organization and the “South African Health Review: Chapters at a glance” for the Health Systems Trust.

Tamara Kredo presented at the Parliamentary Portfolio Committee on Health Meeting on the National Health Insurance Bill. Tamara Kredo submitted a grant proposal to the EDCTP on “Global evidence, local adaptation: Enhancing evidence-informed guideline recommendations for newborn and young child health in three countries in sub-Saharan Africa”. She was awarded EUR 3,216,365 for the project. Tamara Kredo was appointed to National Essential Medicines List Committee of COVID-19 Therapeutics to provide patient-focused evidence-based recommendations for managing COVID-19 and inform the national COVID-19 guidelines and the Ministerial Advisory Committee on COVID-19 Vaccines for the enhanced and integrated response to COVID-19. She was appointed Associate Professor Extraordinary in the Department of Medicine and Department of Global Health at Stellenbosch University and Honorary Associate Professor, School of Public Health and Family Medicine, University of Cape Town.

Solange Duraó was elected to the Cochrane Geographic Group Executive and appointed as a member of the World Health Organization Guideline Development: Management of adolescents 10-19 years of age with obesity for improved health, functioning and reduced disability: a primary health care approach.

Sara Cooper and Charles Wiysonge were appointed to the Ministerial Advisory Committee on COVID-19 Technical Working Group on Vaccine Hesitancy.

Duduzile Ndwandwe successfully defended her research project with distinction for Master in vaccinology course with University of Lausanne.

Charles Wiysonge was awarded funding of R 1,221,044 by the University of Cape Town to develop and implement Evidence Informed Decision-making training modules.

Tamara Kredo was awarded funding of Euro 3,216,366 by EDCTP for the project “Global evidence, local adaptation: Enhancing evidence-informed guideline recommendations for newborn and young child health in three countries in sub-Saharan Africa”

Staff were interviewed by various local and international print and broadcasting media on vaccines and COVID-19.

Staff presented at international (7 invited, 9 orals, 6 posters, 4 round tables, 3 workshops) and local (6 invited, 7 orals, 1 round table, 4 workshops) conferences.

Cochrane SA held its first virtual national symposium in November 2021. Two hundred and fifty delegates attended the symposium which consisted of three plenaries, four workshops and one networking session.

Cochrane SA facilitated and/or hosted 16 webinars, 10 lectures and 3 virtual workshops as part of its capacity building initiatives. Cochrane SA provided free access to the Cochrane Interactive Learning: Conducting an Intervention Review online modules to 19 South African participants (four were from historically disadvantaged institutions) who attended the online Protocol Development course.

We provided bursaries to 14 researchers/students from the University of the Western Cape (3), University of Venda (5), Sefako Makgatho Health Sciences University (3) and the SAMRC (3) to attend the Systematic review and meta-analysis course at Stellenbosch University. We also provided bursaries to 21 participants of which six were from historically disadvantaged institutions (HDIs) to attend the Primer in systematic reviews course at Stellenbosch University from 1 November to 20 December 2021. Bursaries were awarded to six recipients (3 SAMRC staff; 1 from the Department of Health and 2 were from HDIs) to attend Evidence Informed Decision Making and Knowledge Translation courses.

JOURNAL ARTICLES

1. Iwu-Jaja CJ, Jordan P, Ngcobo N, **Jaca A**, Iwu CD, Mulenga M, **Wiysonge C**. Improving the availability of vaccines in primary healthcare facilities in South Africa: is the time right for a system redesign process? *Hum Vaccin Immunother*. 2022 Mar 29;1-7. doi: 10.1080/21645515.2021.1926184
2. Cooper PA, **Cooper S**. Why Parents Refuse Vaccination for Their Children: A South African Perspective. *Wits Journal of Clinical Medicine* 2022;4(1):57-60. doi:10.18772/26180197.2022.v4n1a8
3. Nasir ZH, Mertz D, Nieuwlaat R, Santesso N, Lotfi T, Motilall A, Moja L, Mbuagbaw L, Klugar M, Turgeon AF, Mathew JL, Canelo-Aybar C, Pottie K, Dewidar O, Langendam MW, Iorio A, Vist GE, Meerpohl JJ, Flottorp S, **Kredo T**, Piggott T, Mathews M, et al. eCOVID-19 recommendations map Collaborators. An evaluation of the eCOVID19 Recommendation Map identified diverging Clinical and Public Health guidance. *J Clin Epidemiol* 2022 Mar 23:S0895-4356(22)00069-5. doi:
4. Merson L, **Ndwandwe D**, **Malinga T**, Paparella G, Oneil K, Karam G, Terry RF. Promotion of data sharing needs more than an emergency: An analysis of trends across clinical trials registered on the International Clinical Trials Registry Platform. *Wellcome Open Res* 2022 Mar 21, 7:101. doi: 10.12688/wellcomeopenres.17700.1
5. Dhana A, Hamada Y, Kengne AP, Kerkhoff AD, Rangaka MX, **Kredo T**, Baddeley A, Miller C, Gupta-Wright A, Fielding K, Wood R, Huerga H, Rücker SCM, Heidebrecht C, Wilson D, Bjerrum S, Johansen IS, Thit SS, Kyi MM, Hanson J, Barr DA, Meintjes G, Maartens G. Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis. *Lancet HIV* 2022 Mar 17:S2352-3018(22)00002-9. doi: 10.1016/S2352-3018(22)00002-9
6. Oduwole EO, Laurenzi CA, Mahomed H, **Wiysonge CS**. Enhancing Routine Childhood Vaccination Uptake in the Cape Metropolitan District, South Africa: Perspectives and Recommendations from Point-of-Care Vaccinators. *Vaccines* 2022 Mar 16;10(3):453. doi: 10.3390/vaccines10030453
7. COVID-19 Excess Mortality Collaborators (incl. **Wiysonge CS**). Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. *Lancet* 2022 Mar 10. doi: 10.1016/S0140-6736(21)02796-3
8. Haladou M, Anya BM, Oumarou B, El Khalef I, Biey JN, Harouna H, Katoto P, **Wiysonge CS**. Active search for COVID-19 cases during integrated supportive supervision using an electronic platform to improve healthcare workers performance in Niger: the legacy of the polio eradication program. *Pan African Medical Journal* 2022;41:187. [doi: 10.11604/pamj.2022.41.187.26820]
9. COVID-19 National Preparedness Collaborators (incl. **Wiysonge CS**). Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. *Lancet* 2022 Feb 1. doi: 10.1016/S0140-6736(22)00172-6
10. COVID-19 Forecasting Team (incl. **Wiysonge CS**). Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. *Lancet* 2022 Feb 24. doi: 10.1016/S0140-6736(21)02867-1

11. Glenton C, Lewin S, Downe S, Paulsen E, Munabi-Babigumira S, Agarwal S, Ames H, **Cooper S**, Daniels K, Houghton C, Karimi-Shahanjari A, Moloji H, Odendaal W, Shakibazadeh, Vasudevan L, Xyrichis A, Bohren MA. Cochrane Effective Practice and Organisation of Care (EPOC) qualitative evidence syntheses, differences from reviews of intervention effectiveness and implications for guidance. *International Journal of Qualitative Methods* 2022;21:1-14.
12. Katoto PDMC, Parker S, Coulson N, Pillay N, **Cooper S, Jaca A, Mavundza E**, Houston G, Groenewald C, Essack Z, Simmonds J, Shandu LD, Couch M, Khuzwayo N, Ncube N, Bhengu P, van Rooyen H, **Wiysonge CS**. Predictors of COVID-19 Vaccine Hesitancy in South African Local Communities: The VaxScenes Study. *Vaccines* 2022 Feb 25;10(3):353. doi: 10.3390/vaccines10030353
13. Ngandu NK, Mmotsa TM, Dassaye R, Thabetha A, Odendaal W, Langdown N, **Ndwandwe D**. Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review. *BMC Infectious Diseases* 2022;22(1): e057474. doi: 10.1136/bmjopen-2021-057474
14. Uthman OA, Adetokunboh OO, **Wiysonge CS**, Al-Awlaqi S, Hanefeld J, El Bcheraoui C. Classification Schemes of COVID-19 High Risk Areas and Resulting Policies: A Rapid Review. *Frontiers in Public Health* 2022 Feb 25;10: 769174. doi: 10.3389/fpubh.2022.769174
15. Zhao Y, **Hohlfeld A**, Namale P, Meintjes G, Maartens G, Engel ME. Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: a systematic review and meta-analysis of randomised trials. *Journal of Acquired Immune Deficiency Syndromes* 2022 Feb 14. doi: 10.1097/QAI.0000000000002937
16. **Jaca A**, Malinga T, Iwu-Jaja CJ, Nnaji CA, Okeibunor JC, Kamuya D, **Wiysonge CS**. Strengthening the Health System as a Strategy to Achieving a Universal Health Coverage in Underprivileged Communities in Africa: A Scoping Review. *International Journal of Environmental Research and Public Health* 2022 Jan 5;19(1):587. doi: 10.3390/ijerph19010587
17. Achoki T, Sartorius B, Watkins D, Glenn SD, Kengne AP, Oni T, **Wiysonge CS**, Walker A (incl. **Ndwandwe DE**). Health trends, inequalities and opportunities in South Africa's provinces, 1990-2019: findings from the Global Burden of Disease 2019 Study. *J Epidemiol Community Health* 2022 Jan 19;jech-2021-217480. doi: 10.1136/jech-2021-217480
18. **Ndwandwe DE**, Runeyi S, Pienaar E, **Mathebula L, Hohlfeld A, Wiysonge CS**. Practices and trends in clinical trial registration in the Pan African Clinical Trials Registry (PACTR): a descriptive analysis of registration data. *BMJ Open* 2022 Jan 25;12(1):e057474. doi: 10.1136/bmjopen-2021-057474
19. **Wiysonge CS**, Alobwede SM, de Marie C, Katoto P, Kidzeru EB, Lumngwena EN, **Cooper S**, Goliath R, Jackson A, Shey MS. COVID-19 vaccine acceptance and hesitancy among healthcare workers in South Africa. *Expert Review of Vaccines* 2022 Jan 6:1-11. doi: 10.1080/14760584.2022.2023355
20. **Katoto PDMC**, Aboubacar I, Oumarou B, Adehossi E, Melanga Anya B-P, Mounkaila A, Moustapha A, , Ishagh EK, Diawara GA, Nsiari-Muzeyi BJ, Didier T, **Wiysonge CS**. Clinical features and predictors of mortality among hospitalized patients with COVID-19 in Niger. *Confl Health*. 2021 Dec 14;15(1):89. doi: 10.1186/s13031-021-00426-w
21. Miner MD, Bekker LG, **Kredo T**, Bhagwandin N, Corey L, Gray GE. Meeting report: South African Medical Research Council Standard of Care in Clinical Research in Low- And Middle-Income Settings Summit, November 2017. *Trials* 2021 Nov 6;22(1):778. doi: 10.1186/s13063-021-05754-z
22. **Jaca A**, Sishuba M, Jacobson Vann JC, **Wiysonge CS, Ndwandwe D**. Interventions to improve vaccination uptake among adults (protocol). *Cochrane Database of Systematic Reviews* 2021, Issue 11. Art. No.: CD015057. DOI: 10.1002/14651858.CD015057
23. Dhana A, Hamada Y, Kengne AP, Kerkhoff AD, Rangaka MX, **Kredo T**, et al. Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. *Lancet Infect Dis* 2021 Nov 17:S1473-3099(21)00387-X. doi: 10.1016/S1473-3099(21)00387-X

24. Bergman H, Henschke N, Hungerford D, Pitan F, **Ndwandwe D**, Cunliffe N, Soares-Weiser K. Vaccines for preventing rotavirus diarrhoea: vaccines in use. *Cochrane Database of Systematic Reviews* 2021 Nov 17;11(11):CD008521. doi:10.1002/14651858.CD008521.pub6
25. Oduwole EO, Esterhuizen TM, Mahomed H, **Wiysonge CS**. Estimating vaccine confidence levels among healthcare staff and students of a tertiary institution in South Africa. *Vaccines* 2021 Oct 27;9(11):1246. doi: 10.3390/vaccines9111246
26. Maazou AA, Oumarou B, Bienvenu B, Melanga BP, Didier T, Ishagh EK, Nsiari-Muzeyi BJ, **Katoto P, Wiysonge CS**. Community-based surveillance contribution to the response of COVID-19 in Niger. *Pan African Medical Journal* 2021;40:88. [doi: 10.11604/pamj.2021.40.88.28175]
27. Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV; Local Burden of Disease Anaemia Collaborators, Kassebaum NJ, Hay SI (incl. **Wiysonge CS**). Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. *Nature Medicine* 2021 Oct;27(10):1761-1782. doi: 10.1038/s41591-021-01498-0. Epub 2021 Oct 12
28. Hoevelmann J, Muller E, **Hohlfeld A**, Böhm M, Sliwa K, Engel ME, Viljoen CA. Outcomes and complications of peripartum cardiomyopathy: protocol for a systematic review and meta-analysis. *BMJ Open* 2021 Oct 12;11(10):e054994. doi:10.1136/bmjopen-2021-054994
29. Farmer A, Bobrow K, Leon N, Williams N, Phiri E, Namadingo H, **Cooper S**, et al. Digital messaging to support control for type 2 diabetes (StAR2D): a multicentre randomised controlled trial. *BMC Public Health* 2021 Oct 21;21(1):1907. doi: 10.1186/s12889-021-11874-7
30. **Cooper S**, Schmidt BM, Sambala EZ, Swartz A, Colvin CJ, Leon N, **Wiysonge CS**. Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. *Cochrane Database of Systematic Reviews* 2021 Oct 27;10(10):CD013265. doi: 10.1002/14651858.CD013265.pub2
31. COVID-19 Mental Disorders Collaborators (incl. **Wiysonge CS**). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet* 2021 Nov 6;398(10312):1700-1712. doi:10.1016/S0140-6736(21)02143-7. Epub 2021 Oct 8
32. Batoure AA, Batoure O, Anya BPM, Tambwe D, Baruani B, Biey JNM, **Katoto P, Wiysonge CS**. Forced migration as a risk factor for COVID-19 infection in Africa: insight from Agadez, Niger. *Pan African Medical Journal* 2021;40:97. [doi: 10.11604/pamj.2021.40.97.28116]
33. Glenton C, Lewin S, Downe S, Paulsen E, Munabi-Babigumira S, Johansen M, Agarwal S, Ames, H, **Cooper, S**. et al. Qualitative Evidence Syntheses within Cochrane Effective Practice and Organisation of Care: Developing a template and guidance. *International Journal of Qualitative Methods* 2021 20:16094069211041959. doi: 10.1177/16094069211041959
34. Mbuagbaw L, Schoonees A, **Oliver J**, Arikpo D, **Durão S**, Effa E, **Hohlfeld A, Kredo T, Wiysonge CS**, Young T. Publication practices of sub-Saharan African Cochrane authors: a bibliometric study. *BMJ Open*. 2021 Sep 28;11(9):e051839. doi: 10.1136/bmjopen-2021-051839
35. **Hohlfeld AS**, Ebrahim S, Zaki Shaik M, **Kredo T**. Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions: A Cochrane review. *BJU Int*. 2021 Sep 29. doi: 10.1111/bju.15604
36. Lotfi T, Hajizadeh A, Moja L, Akl EA, Piggott T, **Kredo T**, Langendam MW, Iorio A, Klugar M, Klugarová J, Neumann I, Wiercioch W, Leontiadis GI, Mbuagbaw L, Turgeon AF, Meerpohl J, Stevens A, Brozek J, Santesso N, Pottie K, Dewidar O, Flottorp SA, Karpusheff J, Saz-Parkinson Z, Rojas MX, Parmelli E, Chu DK, Tugwell P, Welch V, Avey MT, Brignardello-Petersen R, Mathew JL, Munn Z, Nieuwlaat R, Ford N, Qaseem A, Askie LM, Schünemann HJ. A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. *J Clin Epidemiol*. 2021 Sep 22:S0895-4356(21)00314-0. doi: 10.1016/j.jclinepi.2021.09.028

37. GBD 2019 Under-5 Mortality Collaborators (including **Wiysonge CS**). Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. *Lancet*. 2021 Sep 4;398(10303):870-905. doi: 10.1016/S0140-6736(21)01207-1
38. Pizarro AB, Persad E, **Durao S**, Nussbaumer-Streit B, Garritty C, Engela-Volker JS, McElvenny D, Rhodes S, Stocking K, Fletcher T, Van Tongeren M, Martin C, Noertjojo K, Sampson O, Jørgensen KJ, Bruschetti M. Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings (Protocol). *Cochrane Database of Systematic Reviews* 2021, Issue 9. Art. No.: CD015112. DOI:10.1002/14651858.CD015112
39. Parrish AG, Blockman M, Cohen K, Dawood H, de Waal R, Gray AL, **Kredo T**, Leong TD, Nel J, Rees H, Reubenson G. Meta-analytic magic, ivermectin, and socially responsible reporting. *South African Medical Journal S Afr Med J*; 17 August 2021. <https://doi.org/10.7196/SAMJ.2021.v111i10.16021>
40. **Cooper S, Wiysonge CS**. Editorial overview: Applying an implementation science lens to vaccines. *Current Opinion in Immunology* 2021 Aug;71:iii-vi. doi:10.1016/j.coi.2021.08.002
41. Oduwole EO, Mahomed H, Laurenzi CA, Larson HJ, **Wiysonge CS**. Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. *Vaccine* 2021 Aug 24;S0264-410X(21)01102-6. doi:10.1016/j.vaccine.2021.08.054
42. Leon N, Namadingo H, **Cooper S**, Bobrow K, Mwantisi C, Nyasulu M, Sicwebu N, Crampin A, Levitt N, Farmer A. Process evaluation of a brief messaging intervention to improve diabetes treatment adherence in sub-Saharan Africa. *BMC Public Health* 2021 Aug 21;21(1):1576. doi: 10.1186/s12889-021-11552-8
43. Riad A, Schünemann H, Attia S, Perić TP, Žuljević MF, Jürisson M, Kalda R, Lang K, Morankar S, Yesuf EA, Mekhemar M, Danso-Appiah A, Sofi-Mahmudi A, Pérez- Gaxiola G, Dziedzic A, Apóstolo J, Cardoso D, Marc J, Moreno-Casbas M, **Wiysonge CS**, et al. Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects. *Int J Environ Res Public Health* 2021 Jul 25;18(15):7859. doi: 10.3390/ijerph18157859
44. Spies R, Potter M, Hollamby R, van der Walt S, **Hohlfeld A**, Ochodo E, van Zyl-Smit RN. Sputum colour as a marker for bacteria in acute exacerbations of COPD: protocol for a systematic review and meta-analysis. *Syst Rev* 2021 Jul 27;10(1):211. doi: 10.1186/s13643-021-01767-6
45. Iwu-Jaja CJ, **Jaca A**, Jaja IF, Jordan P, Bhengu P, Iwu CD, Okeibunor J, Karamagi H, Tumusiime P, Fuller W, Yahaya AA, **Wiysonge C**, Gahimbare L. Preventing and managing antimicrobial resistance in the African region: A scoping review protocol. *PLoS One* 2021 Jul 14;16(7):e0254737. doi:10.1371/journal.pone.0254737
46. GBD 2020, Release 1, Vaccine Coverage Collaborators including **Wiysonge CS**. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. *Lancet* 2021 Jul 14;S0140-6736(21)00984-3. doi: 10.1016/S0140-6736(21)00984-3
47. Wilkinson M, Hofman KJ, Young T, Schmidt BM, **Kredo T**. Health economic evidence in clinical guidelines in South Africa: a mixed-methods study. *BMC Health Serv Res* 2021 Jul 26;21(1):738. doi: 10.1186/s12913-021-06747-z
48. Machingaidze S, **Wiysonge CS**. Understanding COVID-19 vaccine hesitancy. *Nat Med* 2021 Jul 16. doi: 10.1038/s41591-021-01459-7
49. **Cooper S**, van Rooyen H, **Wiysonge CS**. COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines. *Expert Rev Vaccines* 2021 Jul 12:1-13. doi: 10.1080/14760584.2021.1949291
50. **Ndwandwe D, Wiysonge CS**. COVID-19 vaccines. *Current Opinion in Immunology* 2021, 71. <https://doi.org/10.1016/j.coi.2021.07.003>
51. Mbuagbaw L, Wafeu GS, **Kredo T, Durao S, Oliver J, Wiysonge CS**, Ongolo Zogo P. Cochrane Cameroon: bringing Cochrane to Francophone sub-Saharan Africa. *Pan African Medical Journal* 2021;39:166. [doi: 10.11604/pamj.2021.39.166.30508]

52. Abdoulaye MB, Oumarou B, Moussa H, Melanga Anya B-P, Didier T, Nsiari-muzeyi BJ, Katoto P, **Wiysonge CS**. Impact de la pandémie de la COVID-19 sur l' utilisation des services de santé dans la ville de Niamey: une analyse dans 17 formations sanitaires de janvier à Juin 2020 [The impact of the COVID-19 pandemic on health service utilisation in the City of Niamey: a study conducted in 17 health care facilities from January to June 2020]. *Pan African Medical Journal* 2021;39:159. [doi: 10.11604/pamj.2021.39.159.28282]
53. Nnaji CA, **Ndwanwe D**, Lesosky M, Mahomed H, **Wiysonge CS**. Tackling missed opportunities for vaccination in a new era of immunisation. *Lancet* 2021 Jun 2:S0140-6736(21)01226-5. doi: 10.1016/S0140-6736(21)01226-5
54. Adetokunboh O, Iwu-Jaja CJ, Nnaji CA, **Ndwanwe D**. Missed opportunities for vaccination in Africa. *Curr Opin Immunol* 2021 Jun 1;71:55-61. doi:10.1016/j.coi.2021.05.002
55. Razai MS, Oakeshott P, Esmail A, **Wiysonge CS**, Viswanath K, Mills MC. COVID-19 vaccine hesitancy: the five Cs to tackle behavioural and sociodemographic factors. *J R Soc Med* 2021 Jun;114(6):295-298. doi: 10.1177/01410768211018951
56. Bhattacharjee NV, Schaeffer LE, Hay SI; Local Burden of Disease Exclusive Breastfeeding Collaborators (including **Wiysonge CS**, **Ndwanwe DE**). Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000-2018. *Nat Hum Behav* 2021 Jun 3. doi:10.1038/s41562-021-01108-6
57. Tankwanchi AS, Bowman B, Garrison M, Larson H, **Wiysonge CS**. Vaccine hesitancy in migrant communities: a rapid review of latest evidence. *Curr Opin Immunol* 2021 Jun 9;71:62-68. doi: 10.1016/j.coi.2021.05.009
58. **Mavundza EJ**, Iwu-Jaja CJ, Wiyeh AB, Gausi B, Abdullahi LH, Halle-Ekane G, **Wiysonge CS**. A systematic review of interventions to improve HPV vaccination coverage. *Vaccines* 2021; 9(7):687. doi.org/10.3390/vaccines9070687
59. Uthman OA, **Ndwanwe D**, Uthman MMB, Yaya S, **Wiysonge CS**. Multilevel analysis of individual and contextual factors associated with polio non-vaccination in africa: further analyses to enhance policy and opportunity to save more lives. *Vaccines* 2021; 9(7):683. doi.org/10.3390/vaccines9070683
60. **Cooper S**, van Rooyen H, **Wiysonge CS**. COVID-19 vaccine hesitancy in South Africa: A complex social phenomenon. *SAMJ* 2021. doi.org/10.7196/SAMJ.2021.v111i8.1580
61. Nnaji CA, **Wiysonge CS**, Lesosky M, Mahomed H, **Ndwanwe D**. COVID-19 and the gaping wounds of South Africa's suboptimal immunisation coverage: an implementation research imperative for assessing and addressing missed opportunities for vaccination. *Vaccines* 2021; 9(7):691. doi.org/10.3390/vaccines9070691
62. **Sambala EZ**. Diffusion, mortality and responses to pandemic influenza in Nyasaland, c. 1918–1920. *South African Historical Journal* Jun 2021; DOI: 10.1080/02582473.2021.1938652
63. Local Burden of Disease HIV Collaborators (including **Wiysonge CS**). Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study. *Lancet HIV* 2021 Jun;8(6):e363-e375. doi:10.1016/S2352-3018(21)00051-5
64. **Jaca A**, Iwu-Jaja CJ, Balakrishna Y, **Pienaar E**, **Wiysonge CS**. A global bibliometric analysis of research productivity on vaccine hesitancy from 1974 to 2019. *Hum Vaccin Immunother* 2021 May 3:1-7. doi: 10.1080/21645515.2021.1903294
65. Oduwole EO, Mahomed H, Ayele BT, **Wiysonge CS**. Estimating vaccine confidence levels among healthcare students and staff of a tertiary institution in South Africa: protocol of a cross-sectional survey. *BMJ Open* 2021 May 13;11(5):e049877. doi: 10.1136/bmjopen-2021-049877
66. Tamandjou Tchuem CR, Andersson MI, **Wiysonge CS**, Mufenda J, Preiser W, Cleary S. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis. *Vaccine* 2021 May 27;39(23):3141-3151. doi:10.1016/j.vaccine.2021.04.041
67. Nnaji CA, **Wiysonge CS**, Okeibunor JC, Malinga T, Adamu AA, Tumusiime P, Karamagi H. Implementation research approaches to promoting universal health coverage in Africa: a scoping review. *BMC Health Serv Res* 2021 May 3;21(1):414. doi: 10.1186/s12913-021-06449-6

68. Shapiro GK, Kaufman J, Brewer NT, Wiley K, Menning L, Leask J; BeSD Working Group including **Wiysonge CS**. A critical review of measures of childhood vaccine confidence. *Curr Opin Immunol* 2021 May 14;71:34-45. doi: 10.1016/j.coi.2021.04.002
69. Atuhaire L, **Adetokunboh O**, Shumba C, Nyasulu PS. Effect of community-based interventions targeting female sex workers along the HIV care cascade in sub-Saharan Africa: a systematic review and meta-analysis. *Syst Rev* 2021 May 6;10(1):137. doi: 10.1186/s13643-021-01688-4
70. **Jaca A**, Wiyeh AB, Sambala EZ, **Wiysonge CS**. The burden of meningococcal meningitis in the African Meningitis Belt, from 2009-2014: A trend analysis. *Pan African Medical Journal* 2021;39:57. [doi:10.11604/pamj.2021.39.57.17629]
71. Jessani NS, Rohwer A, **Schmidt BM**, Delobelle P. Integrated knowledge translation to advance noncommunicable disease policy and practice in South Africa: application of the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework. *Health Res Policy Syst* 2021 May 17;19(1):82. doi:10.1186/s12961-021-00733-x
72. Leufak AM, **Ndwandwe D**. Applying innovative strategies to achieve Universal Health Coverage in the African Region. *South Eastern European Journal of Public Health* May 2021. DOI: 10.11576/seejph-4447
73. GloPID-R, UKCDR, and COVID-19 Clinical Research Coalition Cross-Working Group on COVID-19 Research in LMICs (including **Wiysonge CS**) Priorities for COVID-19 research response and preparedness in low-resource settings. *Lancet* 2021 May 22;397(10288):1866-1868. doi: 10.1016/S0140-6736(21)00980-6
74. Deignan C, Swartz A, **Cooper S**, Colvin CJ. Stakeholders' understandings of Human Papillomavirus (HPV) Vaccination in Sub-Saharan Africa: A rapid qualitative systematic review. *Vaccines* 2021 May 12;9(5):496. doi:10.3390/vaccines9050496
75. GBD 2019 Tobacco Collaborators (including **Nnaji C**) Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet* 2021 Jun 19;397(10292):2337-2360. doi:10.1016/S0140-6736(21)01169-7
76. GBD 2019 Chewing Tobacco Collaborators (including **Nnaji C**). Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet Public Health* 2021 May 27:S2468-2667(21)00065-7. doi:10.1016/S2468-2667(21)00065-7
77. Mashunye TR, **Ndwandwe DE**, Dube KR, Shey M, Shelton M, **Wiysonge CS**. Fractional dose compared with standard dose inactivated poliovirus vaccine in children: a systematic review and meta-analysis. *Lancet Infect Dis* 2021 Apr 30:S1473-3099(20)30693-9. doi: 10.1016/S1473-3099(20)30693-9
78. Ngcobo N, **Jaca A**, Iwu-Jaja C, **Mavundza E**. Reflection: burden of cervical cancer in Sub-Saharan Africa and progress with HPV vaccination. *Curr Opin Immunol* 2021 Apr 12;71:21-26. doi: 10.1016/j.coi.2021.03.006
79. Lotfi T, Stevens A, Akl EA, Falavigna M, **Kredo T**, Mathew JL, Schünemann HJ, eCOVID Collaborators. Getting trustworthy guidelines into the hands of decision-makers and supporting their consideration of contextual factors for implementation globally: recommendation mapping of COVID-19 guidelines. *J Clin Epidemiol* 2021 Apr 6:S0895-4356(21)00116-5. doi: 10.1016/j.jclinepi.2021.03.034

ACKNOWLEDGEMENTS

1. Dhana A, Hamada Y, Kengne AP, Kerkhoff AD, Rangaka MX, Kredo T, Baddeley A, Miller C, Gupta-Wright A, Fielding K, Wood R, Huerga H, Rücker SCM, Heidebrecht C, Wilson D, Bjerrum S, Johansen IS, Thit SS, Kyi MM, Hanson J, Barr DA, Meintjes G, Maartens G. Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis. *Lancet HIV*. 2022 Apr;9(4):e233-e241. doi: 10.1016/S2352-3018(22)00002-9. **Oliver J** acknowledged for conducting the literature searches

2. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. *N Engl J Med* 2022 Mar 3;386(9):847-860. **Wiysonge CS** acknowledged for his role as a member of the clinical severity adjudication committee for the randomised trial
3. Gagliardi AR, Malinowski J, Munn Z, Peters S, Senerth E. Trends in guideline implementation: an updated scoping review protocol. *JBI Evid Synth*. 2021 Aug 16. doi: 10.11124/JBIES-21-00064. Epub ahead of print. **Kredo T** contributed to the development of eligibility criteria described in the protocol
4. Ehrlich R, Akugizibwe P, Siegfried N, Rees D. The association between silica exposure, silicosis and tuberculosis: a systematic review and meta-analysis. *BMC Public Health*. 2021 May 20;21(1):953. doi: 10.1186/s12889-021-10711-1. **Oliver J** acknowledged for conducting the literature searches

PUBLICATIONS (TECHNICAL/OTHER)

GUIDELINES

1. WHO Guideline Development Team including **Kredo T**. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; March 2022

BOOK CHAPTERS

1. **Wiysonge CS**, Gray GE, Dhai A. The development of vaccines and immunological therapies in pandemics. In: Dhai A, Ballot D, Veller M, eds. *Pandemics and Health Care: Principles, Processes and Practice*. Cape Town, South Africa: Juta and Company (Pty) Ltd 2021:244–261

TECHNICAL REPORTS

1. Leong T, Gray AL, **Kredo T**, de Waal R, Cohen K, Parrish AG, Dawood H. Managing therapeutic uncertainty in the COVID-19 pandemic: rapid evidence syntheses and transparent decision-making in South African Health Review: Chapters at a glance, 8 December 2021
2. World Health Organization (including **Durao S**, Patterson J, **Dauids EL**, **Kredo T**). Assessing the existing evidence base on school food and nutrition policies: a scoping review. Technical Report. Geneva: 2021 (4 May 2021)

RAPID REVIEWS/BRIEF REPORTS

1. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**) Should Nirmatrelvir+RTV be used to treat confirmed COVID-19. Produced for the National Department of Health. Published 14 March 2022
2. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**) Remdesivir for COVID-19: Evidence review of the clinical benefit and harm. Produced for the National Department of Health. Published 15 February 2022 (6th update of the initial 16 April 2020 rapid review report)
3. **Kredo T**, **Ndwandwe D**, Bango F, **Durao S**, Gray C, **Hohlfeld A**, Lessells R, **Mavundza E**, Theunissen H. Johnson & Johnson vaccine (Ad26.COV2.S) homologous boosting as a component of a national COVID-19 prevention strategy : a rapid systematic review report for the Ministerial Advisory Committee on COVID-19 Vaccines workstream 1. 14 December 2021.
4. Rapid Policy Brief Number: 008-01 - COVID-19 vaccine hesitancy in Africa; 2021. Licence: CC BY-NC-SA 3.0 IGO. Prepared by the Information Management Cell of the WHO Regional Office IMST and the Cochrane Africa Network (led by **Wiysonge CS**). Published 13 December 2021
5. **Kredo T**, Bango F, **Durao S**, Gray C, **Hohlfeld A**, Lessells R, **Mavundza E**, **Ndwandwe D**, Theunissen H. Pfizer/BioNtech homologous vaccine booster: a rapid systematic review report for the Ministerial Advisory Committee on COVID-19 Vaccines. 9 December 2021

6. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**) Should baricitinib be used to treat COVID-19? Produced for the National Department of Health. Published 19 November 2021. First update of original 15 August 2021 rapid review report
7. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**) Colchicine for COVID-19: Rapid review of the evidence for clinical benefit and harm. Produced for the National Department of Health. Published 19 November 2021. Third update of original 6 August 2020 rapid review report
8. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**) NSAIDs as treatment for COVID-19. Produced for the National Department of Health. Published 19 November 2021
9. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**) Should fluvoxamine be used to treat COVID-19? Produced for the National Department of Health. Published 5 November 2021
10. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**) Should doxycycline be used in the management of ambulant patients with COVID-19? Produced for the National Department of Health. Published 15 October 2021
11. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**) Should rivaroxaban be used in the management of ambulant COVID-19 patients? Produced for the National Department of Health. Published 8 October 2021
12. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**). Ivermectin for treatment of COVID-19: evidence review of the clinical benefit and harm. Should Ivermectin be used for the management of COVID-19 Produced for the National Department of Health. Published 30 July 2021 (third update of the initial rapid review of 25 January 2021)
13. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**). A review of the optimal dose of either unfractionated heparin or low molecular weight heparin in the prevention of venous thromboembolism in patients with severe COVID-19: evidence review of the clinical benefit and harm. Produced for the National Department of Health. Published 30 July 2021 (second update of the initial rapid review of 19 June 2020)
14. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**). Addendum to the rapid review report of Ivermectin for COVID-19 update, of 18 June 2021. Appraisal of the systematic review by Byrant et al. on use of Ivermectin for treatment and prevention of COVID-19. Published 2 July 2021
15. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T, Hohlfeld A**). Inhaled corticosteroids in ambulatory and hospitalised patients with COVID-19, not requiring oxygen therapy. Produced for the National Department of Health. Published 9 July 2021
16. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**). Ivermectin for the treatment of COVID-19: Evidence review of the clinical benefit and harm. Produced for the National Department of Health. Published 18 June 2021. Update of the initial review of 25 January 2021
17. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T, Durao S**). Vitamin C for SARS-COV-2. Produced for the National Department of Health. Published 28 May 2021
18. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**). Tocilizumab for the treatment of COVID-19: Evidence review of the clinical benefit and harm. Produced for the National Department of Health. Published 26 May 2021. Third update of the initial review of 15 April 2020

19. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**). Convalescent plasma for COVID-19: Evidence review of the clinical benefit and harm. Produced for the National Department of Health. Published 9 April 2021. Update of initial review of 11 June 2020
20. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**). Azithromycin for COVID-19: Evidence review of the clinical benefit and harm. Produced for the National Department of Health. Published 9 April 2021. Update of initial review of 11 May 2020
21. Therapeutic Guidelines Sub-Committee for COVID-19 Management Clinical Guidelines Committee (including **Kredo T**). Interferon for COVID-19: Evidence review of the clinical benefit and harm. Produced for the National Department of Health. Published 9 April 2021. Third update of initial review dated 29 March 2020
22. Inter-Ministerial Advisory Committee (MAC) Technical Working Group on Vaccine Hesitancy (including **Cooper S**). Covid-19 vaccine hesitancy in South Africa: Summary of existing studies. Published 4 April 2021. <https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/>

OTHER

1. **Cooper S**. Interviewed by Danwatch (<https://danwatch.dk/en/about-danwatch/>), a Danish independent media and research centre, on COVID-19 vaccine hesitancy in Africa. 25 January 2022
2. **Wiysonge CS**. Interviewed by the Swedish TV on “vaccine hesitancy in South Africa and sub-Saharan Africa” on 17 December 2021. <https://www.svtplay.se/video/31742562/aktuellt/aktuellt-17-dec-21-00-3?position=648&id=e3vkdd4>
3. **Cooper S, Wiysonge CS**. Understanding vaccine hesitancy in South Africa. *The Conversation*; 14 December 2021. <https://theconversation.com/understanding-vaccine-hesitancy-in-south-africa-173703>
4. **Wiysonge CS**. Interviewed by Radio 786 (South Africa) on the “Omicron variant and the 4th wave of COVID-19 infections in South Africa” on 9 December 2021
5. **Wiysonge CS**. Interviewed by BBC World Service (UK) on “COVID-19 vaccine hesitancy in South Africa and efforts to encourage vaccine uptake” on 1 December 2021
6. **Wiysonge CS**. Interviewed by the Australian Broadcasting Corporation on “COVID-19 vaccine hesitancy in South Africa” in November 2021. <https://www.rnz.co.nz/news/world/456705/omicron-variant-south-africa-battles-vaccine-hesitancy-conspiracy-theories>
7. **Wiysonge CS**. Interviewed by El Confidencial newspaper, one of the main media outlets in Spain, on progress with COVID-19 vaccination on the African continent. 27 November 2021
8. **Wiysonge CS**. Interviewed by Radio Smile 904 FM (South Africa) on “COVID-19 vaccine hesitancy among parents in South Africa” on 23 November 2021
9. **Cooper S**. Interviewed on eNCA "COVID-19 vaccine - Why are parents reluctant?" on 19 November 2021. <https://www.youtube.com/watch?v=IZhYmY-dQx8>
10. **Wiysonge CS**. Interviewed by eNCA on "COVID-19 vaccine hesitancy among parents" on 17 November 2021
11. **Cooper S, Schmidt B, Sambala EZ, Swartz A, Colvin CJ, Leon N, Wiysonge CS**. Unpacking parents’ reasons for not vaccinating their children: why it matters. *The Conversation*. 16 November 2021. <https://theconversation.com/unpacking-parents-reasons-for-not-vaccinating-their-children-why-it-matters-171527>
12. **Ndwandwe D**. Interviewed for the Nature news feature “African scientists race to test COVID drugs-but face major hurdles” *Nature* 599, 25-27 (2021). doi: <https://doi.org/10.1038/d41586-021-02995-5>. 3 November 2021. <https://www.nature.com/articles/d41586-021-02995-5>

13. **Wiysonge CS.** Interviewed by UCT News in October 2021 on a study showing the impact of the COVID-19 pandemic on mental health and reported in multiple media, including “The South African”. <https://www.thesouthafrican.com/news/depression-anxiety-stress-burn-out-covid-19-treatment-uct/>
14. **Wiysonge CS.** Interviewed by the German Deutsche Welle TV on “COVID-19 vaccination progress in Africa - also regarding the vaccination mandate in Zimbabwe”. 25 October 2021. <https://www.dw.com/en/covid-19-special-zimbabwes-vaccine-mandate/av-59620413>
15. **Wiysonge CS.** Interviewed by eNCA on “Vaccine production in Africa key to pandemic-proofing the Continent”. 23 October 2021
16. **Wiysonge CS.** Interviewed by Radio Veritas (South Africa) on the implications of getting children between 12 and 17 vaccinated against COVID-19. 19 October 2021
17. **Wiysonge CS.** Interviewed by Radio 786 (South Africa) on “antiviral pills for COVID-19” on 4 October 2021
18. **Wiysonge CS.** interviewed on DW News TV. Why South Africans are so reluctant to get vaccinated. 13 September 2021. <https://www.youtube.com/watch?v=szd9lznEpBE>
19. **Wiysonge CS.** interviewed for News24 article. When empathy meets evidence: Tackling Covid-19 vaccine hesitancy in SA. 6 September 2021. <https://www.news24.com/health24/medical/infectious-diseases/coronavirus/when-empathy-meets-evidence-tackling-covid-19-vaccine-hesitancy-in-sa-20210906>
20. **Wiysonge CS.** interviewed for iAfrica article. Vaccine Production In Africa Key To Pandemic-Proofing The Continent. 20 September 2021. <https://iafrica.com/vaccine-production-in-africa-key-to-pandemic-proofing-the-continent/>
21. **Wiysonge CS.** Interviewed on Newzroom Africa Health hub on vaccine hesitancy on 29 August 2021. https://youtu.be/Jl7rm_XspJM
22. **Kredo T.** Interviewed on ENCA on Ivermectin on 24 August 2021
23. **Kredo T.** Interviewed on CapeTalk on Ivermectin on 24 August 2021. <https://omny.fm/shows/the-morning-review-with-lester-kiewit/sahpra-launches-microsite-to-detect-adverse-effect>
24. **Wiysonge CS.** Interviewed by Radio Islam. High levels of COVID-19 vaccine hesitancy persists and threatens the lives of many. 27 July 2021. <https://radioislam.org.za/a/listen-high-levels-of-covid-19-vaccine-hesitancy-persist-threaten-the-lives-of-many/>
25. **Wiysonge CS.** Interviewed and quoted in the Saturday Star article "Scientists believe that a multi-pronged approach could be vital to fight COVID-19 vaccine hesitancy". Published in the Saturday Star, 24 July 2021. <https://www.iol.co.za/saturday-star/news/scientists-believe-that-a-multi-pronged-approach-could-be-vital-to-fight-covid-19-vaccine-hesitancy-c8e15bb2-d381-4ce0-b697-f2f107e47024>
26. **Wiysonge CS.** Shining the spotlight on LMICs as part of an inclusive global response. Article published in the GLOPID-R (Global Research Collaboration for Infectious Disease Preparedness) Newsletter. June 2021. <https://www.glopid-r.org/newsletter-articles/newsletter-15th-edition/>
27. **Wiysonge CS** Interviewed and quoted in The Economist article "Africa's covid-19 vaccination drive is off to a slow start". Published in The Economist, 24 April 2021. <https://www.economist.com/middle-east-and-africa/2021/04/24/africas-covid-19-vaccination-drive-is-off-to-a-slow-start>

CONFERENCES

INTERNATIONAL

Invited Speaker

1. **Cooper S.** *Vaccine hesitancy: what makes COVID-19 vaccines different?* Executive Education: Effective ways to increase vaccination rates, Columbia University, USA. 27 September – 1 October 2021
2. **Cooper S.** *Applying GRADE-CERQual to third-order review findings: A worked example from an EPOC QES on factors influencing parents' views and practices regarding childhood vaccination.* Presentation given to the GRADE-CERQual Coordinating Team. Virtual. 21 September 2021
3. **Durao S.** *Advocating for Evidence.* Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021
4. **Wiysonge CS.** *Improving quality of healthcare delivery for universal health coverage.* Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021
5. **Kredo T.** *Rapid reviews in the face of emerging diseases.* Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021
6. **Wiysonge CS.** *Global Research Collaboration for Infectious Disease Preparedness and Response.* COVID-19 Meeting: Addressing neglected COVID-19 research priorities in low-resource settings, Virtual. 17 June 2021
7. **Durao S.** *Innovative and combined approaches to evidence-based agriculture.* Environmental Evidence Summit: Advances in agricultural evidence, Virtual. 13 April 2021

Oral Presentations

1. **Wiysonge CS.** *Vaccine hesitancy.* Urgent Forum on COVID-19, jointly hosted by Australian National Health and Medical Research Council and the South African Medical Research Council. Virtual. 2 December 2021
2. **Wiysonge CS.** *Strategies to improve HPV Vaccine Confidence.* Africa HPV Vaccine Forum. Virtual. 30 November 2021
3. **Wiysonge CS.** *Developing a COVID-19 Vaccine Strategy for Africa.* 7th African Conference on One Health and Biosecurity, Civic Centre Victoria Island, Lagos State, Nigeria. 27-29 October 2021
4. **Wiysonge CS.** *Vaccinology, vaccine hesitancy, and other cross-cultural factors impacting on the Covid-19 pandemic Africa.* Africa Health Congress & Exhibition. Virtual. 25-29 October 2021
5. **Wiysonge CS.** *Vaccine policy, vaccine usage and vaccine hesitancy in South Africa.* Sub-Saharan Africa Webinar on Regional COVID-19 Updates. Virtual. 25-29 October 2021
6. **Wiysonge CS.** *Outcome of Roundtable 2 on Production and Synthesis of Evidence.* Cochrane Convenes. Virtual. 14 October 2021
7. **Cooper S.** *Vaccine Webinar Series, Webinar 3 'Building Community Trust for COVID-19 Vaccine Confidence and Deployment'.* Social Science Working Group of the COVID-19 Clinical Research Coalition. Virtual, 14 October 2021
8. **Wiysonge CS.** *Overcoming hesitancy in early pandemic phase.* OECD Global Science Forum workshop on priority setting and coordination of the scientific response to COVID-19 and looking ahead to the next crisis. Virtual, 4-5 October 2021
9. Naude C, **Durao S.** *Cochrane Nutrition: What is it all about?* 2021 WHO/Cochrane/Cornell University Summer Institute for Systematic Reviews in Nutrition for Global Policy Making, Virtual. 3 August 2021

Posters

1. Leong TD, Gray AL, **Kredo T**, de Waal R, Cohen K, Parrish AG, Dawood H. *Rapid evidence reviews to inform COVID-19 treatment guidelines in South Africa.* First International Conference on Public Health in Africa. Virtual, 14-16 December 2021

2. Katoto PDMC, Parker S, **Cooper S**, Coulson N, Pillay N, **Jaca A**, van Rooyen H, **Wiysonge CS**; Vax-Scenes Project Team (including **Mavundza E**). *Predictors of COVID-19 vaccine hesitancy in South African local communities*. First International Conference on Public Health in Africa. Virtual, 14-16 December 2021.
3. **Cooper S, Schmidt BM, Sambala EZ**, Swartz A, Colvin CJ, Leon N, **Wiysonge CS**. Factors influencing parents' acceptance of routine childhood vaccination: A Cochrane qualitative evidence synthesis. Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021
4. **Hohlfeld A, Kredo T, Davids E, Galloway M, Ndwandwe D, Oliver J, Pienaar E, Durao S**. *Strategies to increase access to Cochrane training opportunities in South Africa and the African region*. Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021
5. **Hohlfeld A, Kredo T, Oliver J, Durao S**. *Providing training during the SARS-COV19 pandemic, an Online Protocol Development workshop*. Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021
6. **Durao S**, Visser M, Ramokolo V, Oliviera J, **Schmidt B**, Balakrishna Y, Brand A, Kristjansson E, Schoonees A. *Community-level interventions for improving access to food in low- and middle-income countries: a Cochrane review*. Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021

Round Table

1. **Wiysonge CS**. *WHO online consultation meeting to develop global principles for identifying credible sources of health information on social media*. Virtual. 15 December 2021
2. **Wiysonge CS**. *Africa, Ethics, and COVID-19*. Africa Health Congress & Exhibition. Virtual. 25-29 October 2021
3. **Wiysonge CS**. *Roundtable 2: Production and Synthesis of Evidence – Connecting Primary and Secondary Research*. Cochrane Convenes. Virtual. 6 October 2021
4. **Wiysonge CS**. *Roundtable 7: Getting Political Buy-in for Research*. Cochrane Convenes. Virtual. 6 October 2021

Workshop Facilitator

1. **Kredo T**. Rapid reviews. Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021
2. **Cooper S**, Schmidt BM. Introduction to qualitative research synthesis. Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021
3. **Hohlfeld A**. Risk of bias for non-randomized studies. Cochrane Africa Indaba, Abuja, Nigeria. 13-15 July 2021

LOCAL

Invited Speaker

1. **Wiysonge CS**. *The development of vaccines and immunological therapies in pandemics*. Symposium on Pandemic Preparedness: Lessons from the experts. Wits University, Johannesburg. 23 March 2022.
2. **Ndwandwe D**. *Clinical trial reporting and registration: what communities need to know?* Advocates for the Prevention of HIV in Africa Engagement Forum. 28 March 2022
3. **Durao S**. *Community-level interventions for improving access to food in low- and middle-income countries: A Cochrane Review*. PRICELESS Journal Club. Virtual. 30 September 2021
4. **Durao S**. *Community-level interventions for improving access to food in low- and middle-income countries: A Cochrane Review*. SAMRC UHC/NHI Forum. Virtual. 26 August 2021
5. **Wiysonge CS**. *The Covid-19 vaccine rollout in South Africa: ethical perspectives*. Ethics Alive Seminar, Virtual. Wits University. 6 May 2021
6. **Kredo T**. *Understanding Ivermectin for COVID-19 treatment (risks, benefits and the law)*. Academy of Science of South Africa (ASSAf) Panel Discussion. Virtual. 12 April 2021

Oral Presentations

1. **Kredo T** on behalf of the Work stream 1 subcommittee. *Pfizer/BioNTec homologous vaccine booster: a rapid systematic review*. Ministerial Advisory Committee on COVID-19 Vaccines Meeting, Virtual. 9 December 2021
2. **Mathebula L**. *COVID-19 trials*. Cochrane SA Virtual National Symposium, Cape Town. 25-26 November 2021
3. **Cooper S**. *COVID-19 vaccine hesitancy in South Africa: A rapid review of survey findings*. Cochrane SA Virtual National Symposium, Cape Town. 25-26 November 2021
4. **Wiysonge CS**. *Reasons for vaccine hesitancy in South Africa - what is the evidence?* UCT COVID-19 ECHO Clinic on Vaccine Hesitancy. Virtual. 4 November 2021
5. **Wiysonge CS**. *How to maximise the uptake of COVID-19 vaccines in South Africa*. Wits Webinar Series on Vaccine Hesitancy: Steve Biko Centre for Bioethics. Virtual. 15 October 2021
6. **Wiysonge CS**. *COVID-19 vaccines and vaccination*. Nahana Communication Group Meeting. Virtual. 8 October 2021
7. Jewkes R, Hanmer L, **Kredo T**, Solanki G, Jonas K, Pillay-can Wyk V, Gray G. *National Health Insurance Bill*. Parliamentary Portfolio Committee on Health Meeting, Virtual. 20 May 2021

Round Table

1. **Wiysonge CS**, Lasserson T, Meremikwu M, Mbuagbaw L, Ochodo E. *A conversation - Cochrane into the next decade*. Cochrane SA Virtual National Symposium, Cape Town. 25-26 November 2021

Workshop Facilitator

1. **Hohlfeld A, Oliver J**. *Where does one look for evidence? An introduction to searching*. Cochrane SA Virtual National Symposium, Cape Town. 25-26 November 2021
2. **Mathebula L, Ndwandwe D**. *Clinical trial registration: What we know and how to register*. Cochrane SA Virtual National Symposium, Cape Town. 25-26 November 2021
3. **McCaul M, Kredo T**, Hohlfeld A. *Evidence to Decision (EtD) Guideline Panel Simulation*. Cochrane SA Virtual National Symposium, Cape Town. 25-26 November 2021
4. **Mavundza E, Duroo S**. *Introduction to systematic reviews*. Cochrane SA Virtual National Symposium, Cape Town. 25-26 November 2021

TEACHING AND TRAINING

GRADUATION OF STUDENTS

Student Name and Surname	Gender	Race	Degree	Institution
Villyen Motaze	Male	Non-South African (Permanent resident)	PhD	Stellenbosch University (December 2021)
Anelisa Jaca	Female	African	Postdoc	SAMRC (November 2021)
Duduzile Ndwandwe	Female	African	Masters	Lausanne University (December 2021)

SUPERVISION OF STUDENTS

Student Name and Surname	Gender	Race	Degree	Institution
Achuma Fihla	Female	African	Masters	University of Cape Town
Ameer Hohlfeld	Male	Coloured	PhD	Stellenbosch University
Badee Essau	Male	Coloured	Masters	University of Cape Town
Chukwudi Nnaji	Male	Non-South African (Permanent resident)	PhD	University of Cape Town
Edison Mavundza	Male	African	Postdoc	SAMRC
Elizabeth Moirana	Female	Non-South African	Masters	University of Cape Town
Elizabeth Oduwole	Female	African	PhD	Stellenbosch University
Foad Omran	Male	Non-South African	Masters	University of Cape Town
Khanyisa Msomi	Female	African	Masters	Nelson Mandela University
Lisa Fincham	Female	White	Masters	Stellenbosch University
Meagan Jacobs	Female	Coloured	PhD	University of Cape Town
Monique Koopman	Female	Coloured	Masters	University of Cape Town
Phelele Bhengu	Female	African	PhD	University of Cape Town
Samuel Alobwede	Male	Non-South African (Permanent resident)	PhD	University of Cape Town

LECTURES

1. Evidence to the decision process for guideline panels (EtD) Simulation. Clinical Practice Guideline Course. Masters in Clinical Epidemiology. Stellenbosch University. Virtual. 8 March 2022
2. Introduction to Qualitative Evidence Synthesis (QES). Qualitative Research Methods module for the MPH students at the School of Public Health Summer School Programme, University of the Western Cape. Virtual. 16 February 2022
3. Risk of Bias 2.0 Assessing risk of bias in included studies. Systematic Review and Meta-Analysis, MSc in Clinical Epidemiology, Division of Epidemiology and Biostatistics, Stellenbosch University. Virtual. 4 August 2021
4. Calculating effect sizes: Meta-analysis & Heterogeneity. Evidence-based Healthcare Module 2021 for MPH students at the University of Cape Town. Virtual. 12 August 2021
5. Risk of bias for randomized controlled trials. Evidence-based Healthcare module 2021 for MPH students at the University of Cape Town. Virtual. 26 August and 2 September 2021
6. Introduction to RevMan. Evidence-based Healthcare module 2021 for MPH students at the University of Cape Town. Virtual. 19 August 2021
7. Prospero Registration and publishing a protocol. Evidence-based Healthcare Module 2021 for MPH students at the University of Cape Town. Virtual. 28 July 2021
8. Developing search methods for identifying relevant studies and hands-on searching for relevant studies. Systematic Review and Meta-Analysis, MSc in Clinical Epidemiology, Division of Epidemiology and Biostatistics, University of Stellenbosch. Virtual. 7 July 2021

9. Accessing the evidence. Evidence-based Healthcare Module 2021 for MPH students at the University of Cape Town. Virtual. 27 July 2021
10. Introduction to evidence-based healthcare. Evidence-based Healthcare Module 2021 for MPH students at the University of Cape Town. Virtual. 26 July 2021

WEBINARS

1. Living guideline recommendations. Virtual. 15 March 2022
2. Data Sharing information requirements in ICTRP registries: what have we learnt. COVID-19 Clinical Research Coalition Data Sharing Working Group. Virtual. 9 March 2022
3. A journey of Career transition: from basic molecular science to public health. SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit (MMRU) of the Infectious Disease and Molecular Medicine (IDM). University of Cape Town. 11 February 2022
4. Factors that influence parents' views and practices regarding routine childhood vaccination: Findings from a Cochrane EPOC qualitative evidence synthesis. EPOC Norway, Cochrane Norway and Cochrane South Africa webinar. Virtual. 22 February 2022
5. Primary care management of COVID-19: Up to date and evidence-based case studies. Virtual. 3 February 2022
6. Circumcision devices vs standard surgical techniques in adolescent and adult male circumcisions. Virtual. 17 November 2021
7. CAMELOT and the GRADE CERQual methodological limitations. Virtual. 16 November 2021
8. Evidence synthesis and different types of systematic reviews. Virtual. 19 October 2021
9. What influences vaccination uptake? The development of global tools to assess the behavioural and social drivers of immunization. Virtual. 21 September 2021
10. The PRISMA 2020 statement. Virtual. 17 August 2021
11. Conducting systematic reviews of prevalence. Virtual. 20 July 2021
12. Introduction to systematic reviews of effectiveness. Virtual. 21 September 2021
13. Appraising guidelines using the AGREE II tool. 15 June 2021
14. A Cochrane qualitative evidence synthesis on factors influencing parents' view and practices around routine childhood vaccination: Methods, findings and key challenges. Presentation to the Learning Initiative for eXperienced Authors (LIXA). 27 May 2021
15. Appraising clinical trials using the RoB2 tool. 25 May 2021
16. Appraising observational studies using the ROBINS-I tool. 18 May 2021

WORKSHOPS

1. AMSTAR session: Assessing the methodological quality of systematic reviews using AMSTAR 2. Training session for the Primary Health Care Adult Hospital Level Expert Review Committee Meeting. Virtual. 17 June 2021
2. Protocol Development Course. Virtual. 31 May - 4 June 2021
3. Clinical guidelines training on the InGuide training with Holger Schunemann for the Public Health Canada staff. Virtual. 22 April 2021

INTELLECTUAL INPUT

INTERNATIONAL

Cooper S

1. Peer reviewer, PLOS One. February 2022
2. Co-editor of the Vaccines section of Current Opinion in Immunology. August 2021 -

Durao S

1. Peer review, Journal of Clinical Epidemiology. August 2021
2. Peer reviewer, COVID-19 protocols for African Academy of Sciences. July - August 2021
3. Member, Bursary/Stipend Committee, Cochrane Africa Indaba 2021. June 2021
4. Peer reviewer, BMJ Global Health. June 2021
5. Member, Cochrane Geographic Groups Executive. May 2021 -
6. Member, World Health Organization Guideline Development: Management of adolescents 10-19 years of age with obesity for improved health, functioning and reduced disability: a primary health care approach.

Gloeck N

1. Peer reviewer, International Journal of Mental Health and Addiction. March 2022

Hohlfeld A

1. Peer reviewer, COVID-19 protocols for African Academy of Sciences. July - August 2021

Jaca A

1. Peer reviewer, Systematic Reviews. June 2021

Kredo T

1. Member, External Review Group, PAHO Guideline for preventive chemotherapy for the control of taenia solium taeniasis. November 2020 - September 2021
2. Peer reviewer, Journal International AIDS Society, September 2021
3. Reviewer, PhD thesis, University of Oslo. June 2021
4. Facilitator, WHO consolidated guidelines on management of tuberculosis in children. 31 May - 17 June 2021
5. Facilitator, WHO consolidated guidelines update on the treatment of drug susceptible tuberculosis. 27-30 April 2021

Ndwandwe D

1. Peer reviewer, BMJ Open. March 2022
2. Peer reviewer, Frontiers in Public Health. March 2022
3. Peer reviewer, SAGE Open. February 2022
4. Member, Global Research Collaboration for Infectious Disease Preparedness and Response (GloPID-R) Liaison Committee. Oct 2021
5. Member, Global Research Collaboration for Infectious Disease Preparedness and Response (GloPID-R) Clinical Trials Working Group
6. Peer reviewer, BMJ Open. July 2021
7. Grant application reviewer, National Institute for Health Research. August 2021

8. Examiner, Masters thesis, School of Global Health, Karoliska Institute, Sweden. May 2021

Oliver J

1. Member, eCOVID Evidence Prime RecMap Plain Language Recommendations Citizen Advisory Committee. June 2021 –

Wiysonge CS

1. Member, Independent Advisory Board of the European Integrated Services for Infectious Disease Outbreak Research (ISIDORE). March 2022 -
2. Guest Editor, Healthcare. March 2022 -
3. PhD examiner, Warwick University, UK. March 2022
4. Peer reviewer, BMJ Open. March 2022
5. Chair, Adjudication Committee of Ubuntu (a Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern). February 2022 -
6. Peer reviewer, Nature Medicine. February 2022
7. Peer reviewer, Vaccine. February 2022
8. Peer reviewer, PLoS ONE. February 2022
9. Member, Organising Committee; First International Conference on Public Health in Africa. Virtual; 14-16 December 2021
10. Chair, Session 5 on “Assessing the Response to COVID-19 in Africa to Prepare for Future Health Threats”. First International Conference on Public Health in Africa. Virtual; 14-16 December 2021
11. Chair, Symposium on “Clinical Trial Coordination During the COVID-19 Pandemic: lessons learned”. Tenth EDCTP Forum. Virtual. 21 October 2021
12. Chair, Global Research Collaboration for Infectious Disease Preparedness and Response (GloPID-R) COVID-19 Research in LMICs Working Group Meeting. Virtual. 02 November 2021

LOCAL

Cooper S

1. Member, Social Science Working Group of the COVID-19 Clinical Research Coalition. February 2022 -
2. Peer Reviewer, South African Review of Sociology. February 2022
3. Peer reviewer, South African Review of Sociology. November 2021
4. Member, Ministerial Advisory Committee on COVID-19 Technical Working Group. August 2021 –
5. Peer reviewer, South African Review of Sociology. May 2021

Hohlfeld A

1. Course Convener, Evidence-based Healthcare Module, University of Cape Town. July - December 2021

Kredo T

1. Member, Ministerial Advisory Committee on COVID-19 Vaccines for the enhanced and integrated response to COVID-19. March 2022 -
2. Honorary Associate Professor, School of Public Health and Family Medicine, University of Cape Town. October 2021 - September 2026

3. Associate Professor Extraordinary, Department of Medicine and Department of Global Health at Stellenbosch University. May 2021 - April 2024
4. Member, National Essential Medicines List Committee (NEMLC) on COVID-19 Therapeutics. August 2021 –
5. Member, Assessment Panel, Stellenbosch University MSc thesis protocol evaluation. June 2021

Ndwandwe D

1. Examiner, University of KwaZulu Natal. May 2021
2. Observer and assistant to secretariat, Vaccine Advisory Committee, Workstream 1. April 2021 -
3. Chair, Eh! WOZA. April 2021 –

Wiysonge CS

1. Member, Working Group on COVID-19 Vaccination of Children 5 -11 Years Old, MAC - Vaccines. February 2022 -
2. Member, Western Cape COVID-19 Vaccine Expert Advisory Group. Meetings every other week from October 2021 to December 2021
3. Member, Expert Group leading the development of the COVID-19 County Report on the implementation of measures to combat COVID-19 in South Africa. National Research Foundation (NRF); Department of Planning, Monitoring and Evaluation (DPME); and Government Technical Advisory Centre (GTAC). Monthly meetings from October 2021 to December 2021
4. Member, SAMRC HREC. Monthly meetings from October 2021 to December 2021

GRANTS AWARDED

Funder	Grant Description	Amount
University of Cape Town	Develop training EIDM modules including an implementation plan for the modules	R1,221,044
EDCTP	Global evidence, local adaptation: Enhancing evidence-informed guideline recommendations for newborn and young child health in three countries in sub-Saharan Africa	EUR 3,216,366
African Academy of Sciences	Science engagement to support evidence-informed policy responses to COVID-19 in Africa	US\$ 6,440

TRAINING COURSES

1. **Oliver J.** Information retrieval for living evidence. 7 December 2021
2. **Ndwandwe D.** CREDE Good clinical practice beginner’s course. 21 September 2021. Cost: R 3,652.17
3. **Runeyi S.** CREDE Good clinical practice beginner’s course. 21 September 2021. Cost: R 3,652.17
4. **Mathebula L.** CREDE Good clinical practice beginner’s course. 21 September 2021. Cost: R 3,652.17
5. **Ndwandwe D.** GTAC Public Economics Winter School. 17-19 August 2021. Cost: Nil
6. **Ndwandwe D.** POPIA workshop. Cape Town. June 2021. Cost: Nil
7. **Jaca A.** Working with Journalists (webinar). 24 June 2021. Cost: Nil
8. **Jaca A.** Agree tools: what are they and when to use them? (webinar). 15 June 2021. Cost: Nil

9. **Oliver J.** PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews (webinar). 14 June 2021. Cost: Nil
10. **Jaca A.** Appraising clinical trials using the RoB 2 tool (webinar). 25 May 2021. Cost: Nil
11. **Jaca A.** Appraising observational studies (ROBINS-I) (webinar). 18 May 2021. Cost: Nil
12. **Mavundza E.** Advanced search for systematic reviews and advanced search strategy design for complex topics. York Health Economics Consortium (webinar). 11 & 14 May 2021. Cost: £ 149.99
13. **Hohlfeld A.** Advanced search for systematic reviews and advanced search strategy design for complex topics. York Health Economics Consortium (webinar). 11 & 14 May 2021. Cost: £ 149.99
14. **Ndwandwe D.** 21st Advanced vaccinology course (ADVAC). 9 - 27 May 2022. Cost: Nil

CONFERENCES/MEETINGS ATTENDED

1. **Wiysonge CS** and **Ndwandwe D** attended the General Assembly of the Global Research Collaboration for Infectious Disease Preparedness and Response (GloPID-R). Virtual, 2 December 2021
2. **Wiysonge CS** attended the COVID Research Coordination & Learning (COVID CIRCLE) Steering Group Meeting. Virtual, 8 November 2021
3. **Wiysonge CS** attended the GloPID-R Executive Board Meeting. Virtual, 4 November 2021
4. Cochrane staff attended and presented at the Cochrane South Africa Virtual National Conference. 25-26 November 2021
5. **Wiysonge CS** and **Ndwandwe D** attended the General Assembly of Clinical Research Initiative for Global Health Consortium (CRIGH). Virtual. 21 October 2021
6. **Wiysonge CS** attended a meeting of the African Advisory Committee on Health Research and Development (AACHRD). Virtual, 8 October 2021
7. **Wiysonge CS** and **Ndwandwe D** attended the General Assembly of the Global Research Collaboration for Infectious Disease Preparedness and Response (GloPID-R). Virtual, 7 October 2021
8. Cochrane staff attended and presented at the Cochrane Africa Indaba which was held on 14-15 July 2021.
9. **Ndwandwe D.** Guidelines to mandatory workplace COVID-19 vaccinations symposium. 5 August 2021. Cost: R1,200
10. **Wiysonge CS.** Guidelines to mandatory workplace COVID-19 vaccinations symposium. 5 August 2021. Cost: R1,200
11. **Wiysonge CS.** GloPID-R meeting for Covid19 research in low- and middle-income countries
12. **Kredo T.** Cochrane Governing Board meetings. April, May & June 2021
13. **Kredo T.** Cochrane Governance Board Strategic Session. 22 June 2021
14. **Kredo T.** NEMLC Committee meeting. 24 June 2021
15. **Ndwandwe D.** Vaccine Ministerial Advisory Committee workstream 1 meetings. April, May & June 2021
16. **Ndwandwe D.** Covid-19 Research Coalitions data sharing working group meetings. April, May & June 2021
17. **Ndwandwe D.** Preparedness Planning for Clinical Research During Public Health Emergencies (PREP) meetings. April, May, June 2021

18. **Kredo T.** NEMLC Subcommittee on COVID-19 meeting. April, May & June 2021
19. **Oliver J.** Cochrane Africa Indaba Local Organizing meeting. April, May & June 2021
20. **Jaca A.** Africa's vaccine manufacturing virtual conference. 12-13 April 2021